Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 971-987, December 2007

Systemic lupus erythematosus: modern strategies for management – a moving target

  • Jennifer K. King, MD (Rheumatology Fellow)

      Affiliations

    • Corresponding Author InformationCorresponding author. University of California–Los Angeles, Division of Rheumatology, 1000 Veteran Avenue, Rehab Center 32-59, Los Angeles, CA 90095, USA. Tel.: +1 310 825 7992; fax: +1 310 206 8606.
    • ,
  • Bevra H. Hahn, MD (Chief of Division of Rheumatology, Professor of Medicine)

University of California, Los Angeles, USA

Rapid advances in understanding the immunopathogenesis of systemic lupus erythematosus (SLE) have yielded an unprecedented era of discovery of new targets with therapeutic potential. Recent clinical trials have also shed light on the optimal utility of several traditional therapies used in our SLE armamentarium.

Key words: biologics, cyclophosphamide, monoclonal antibodies, mycophenolate mofetil, systemic lupus erythematosus

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(07)00104-0

doi:10.1016/j.berh.2007.09.002

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 971-987, December 2007

Article Tools

* Image Usage & Resolution